NeuroRx and Relief Therapeutics Approved to Commence Phase 2b/3 Trial for ZYESAMI
NeuroRx and Relief Therapeutics have completed enrollment for their phase 2b/3 clinical trial for their treatment of respiratory failure in patients with severe cases of COVID-19. The trial, who’s top-line data is expected in one month, has...
FDA Risk Evaluation and Mitigation Strategy (REMS) for Fentanyl Products
The U.S. Food and Drug Administration (FDA) has made their REMS requirements for transmucosal immediate-release fentanyl (TIRF) products more rigorous to minimize inappropriate prescriptions for the strong and highly addictive opioid. The REMS guidelines serve as a...
InnoCare Pharma of Beijing Receives China’s National Medical Products Association Approval
The Chinese company InnoCare Pharma announced today (12/28) that its BTK inhibitor orelabrutinib received approval for the treatment of cancer and autoimmune diseases, specifically relapsed/refractory chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma...
Walmart Sued for Prescription Opioid Sales
The Department of Justice sued Walmart yesterday (12/22) for inadequately screening for questionable prescriptions, ultimately fueling the nation’s opioid crisis. According to the lawsuit, Walmart’s understaffed pharmacies pressured employees to fill prescriptions...
FDA Approves First Prostate Cancer Hormone Treatment
Today (12/21) the U.S. Food and Drug Administration (FDA) approved the first oral treatment for prostate cancer, a disease that affects on average one in every nine men. Orgovyx, created by Myovant, was created to treat advanced prostate cancer cases by blocking the...
Moderna COVID-19 Vaccine Receives FDA Emergency Use Authorization
On Friday (12/18) The U.S Food and Drug Administration granted Moderna Emergency Use Authorization for their COVID-19 vaccine in adults over 18 years old. In addition to Pfizer’s vaccine, the U.S government agreed to purchase 200 million doses from Moderna which will...